- Home
- NUVL vs FSS Comparison
NUVL vs FSS Comparison
Compare NUVL & FSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- FSS
- Stock Information
- Founded
- NUVL 2017
- FSS 1901
- Country
- NUVL United States
- FSS United States
- Employees
- NUVL N/A
- FSS N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- FSS Auto Manufacturing
- Sector
- NUVL Health Care
- FSS Consumer Discretionary
- Exchange
- NUVL Nasdaq
- FSS Nasdaq
- Market Cap
- NUVL 4.9B
- FSS 5.2B
- IPO Year
- NUVL 2021
- FSS N/A
- Fundamental
- Price
- NUVL $87.24
- FSS $88.38
- Analyst Decision
- NUVL Strong Buy
- FSS Buy
- Analyst Count
- NUVL 10
- FSS 2
- Target Price
- NUVL $112.60
- FSS $90.00
- AVG Volume (30 Days)
- NUVL 492.9K
- FSS 525.0K
- Earning Date
- NUVL 11-12-2024
- FSS 10-31-2024
- Dividend Yield
- NUVL N/A
- FSS 0.53%
- EPS Growth
- NUVL N/A
- FSS 44.95
- EPS
- NUVL N/A
- FSS 3.45
- Revenue
- NUVL N/A
- FSS $1,837,900,000.00
- Revenue This Year
- NUVL N/A
- FSS $9.83
- Revenue Next Year
- NUVL N/A
- FSS $7.35
- P/E Ratio
- NUVL N/A
- FSS $26.30
- Revenue Growth
- NUVL N/A
- FSS 10.33
- 52 Week Low
- NUVL $56.52
- FSS $68.02
- 52 Week High
- NUVL $113.51
- FSS $102.18
- Technical
- Relative Strength Index (RSI)
- NUVL 38.02
- FSS 54.32
- Support Level
- NUVL $89.62
- FSS $89.97
- Resistance Level
- NUVL $96.24
- FSS $92.99
- Average True Range (ATR)
- NUVL 2.90
- FSS 2.23
- MACD
- NUVL -0.27
- FSS 0.80
- Stochastic Oscillator
- NUVL 15.96
- FSS 78.68
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About FSS Federal Signal Corporation
Federal Signal Corp designs and manufactures products and integrated solutions for municipal, governmental, industrial, and airport customers. It operates in the segments of Environmental Solutions Group and the Safety and Security Systems Group. The Environmental Solutions group manufactures and supplies street sweeper vehicles, sewer cleaner and vacuum loader trucks, hydro-excavation trucks, high-performance water blasting equipment, dump truck bodies, and trailers. The Safety and Security Systems Group offers comprehensive systems and products such as campus and community alerting, emergency vehicles, first responder interoperable communications, and others. The company generates a majority of its revenue from the Environmental Solutions Group segment.